| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 191 | 2023 | 1256 | 23.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 164 | 2023 | 1728 | 16.520 |
Why?
|
| Adiposity | 49 | 2023 | 441 | 13.850 |
Why?
|
| Prenatal Exposure Delayed Effects | 44 | 2023 | 450 | 12.870 |
Why?
|
| Diabetes, Gestational | 35 | 2023 | 217 | 10.230 |
Why?
|
| Body Mass Index | 90 | 2023 | 1856 | 7.910 |
Why?
|
| Pediatric Obesity | 30 | 2023 | 415 | 7.210 |
Why?
|
| Pregnancy | 128 | 2023 | 4402 | 6.870 |
Why?
|
| Birth Weight | 35 | 2023 | 356 | 6.850 |
Why?
|
| Body Composition | 22 | 2023 | 691 | 6.210 |
Why?
|
| Child | 251 | 2023 | 16295 | 5.640 |
Why?
|
| Insulin Resistance | 34 | 2022 | 964 | 5.630 |
Why?
|
| Adolescent | 248 | 2023 | 16735 | 5.190 |
Why?
|
| Obesity | 62 | 2023 | 2468 | 4.840 |
Why?
|
| Infant, Newborn | 91 | 2023 | 4615 | 4.590 |
Why?
|
| Diet | 27 | 2023 | 1015 | 4.490 |
Why?
|
| Cardiovascular Diseases | 41 | 2022 | 1591 | 4.490 |
Why?
|
| Female | 348 | 2023 | 55860 | 4.450 |
Why?
|
| Child Development | 14 | 2022 | 400 | 4.400 |
Why?
|
| Blood Glucose | 55 | 2023 | 1258 | 4.230 |
Why?
|
| Vascular Stiffness | 17 | 2023 | 355 | 4.130 |
Why?
|
| Overnutrition | 7 | 2021 | 35 | 4.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 6 | 2023 | 241 | 3.920 |
Why?
|
| Humans | 441 | 2023 | 106319 | 3.890 |
Why?
|
| Insulin | 44 | 2023 | 1361 | 3.780 |
Why?
|
| Maternal Exposure | 12 | 2022 | 131 | 3.710 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 11 | 2023 | 138 | 3.550 |
Why?
|
| Diabetic Ketoacidosis | 9 | 2022 | 97 | 3.520 |
Why?
|
| Child, Preschool | 104 | 2023 | 8364 | 3.410 |
Why?
|
| Young Adult | 145 | 2023 | 9726 | 3.340 |
Why?
|
| Male | 272 | 2023 | 54589 | 3.290 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 7 | 2021 | 59 | 3.260 |
Why?
|
| Cohort Studies | 76 | 2023 | 4548 | 3.220 |
Why?
|
| Risk Factors | 107 | 2023 | 8179 | 3.180 |
Why?
|
| Diabetes Mellitus | 26 | 2022 | 819 | 3.140 |
Why?
|
| Diabetic Angiopathies | 16 | 2020 | 177 | 3.060 |
Why?
|
| Breast Feeding | 13 | 2020 | 328 | 2.940 |
Why?
|
| Fetal Blood | 15 | 2023 | 239 | 2.840 |
Why?
|
| Longitudinal Studies | 46 | 2023 | 2363 | 2.770 |
Why?
|
| Prospective Studies | 49 | 2023 | 5756 | 2.690 |
Why?
|
| Tobacco Smoke Pollution | 5 | 2022 | 195 | 2.560 |
Why?
|
| Infant | 74 | 2023 | 7332 | 2.560 |
Why?
|
| Prevalence | 62 | 2023 | 2164 | 2.540 |
Why?
|
| Biomarkers | 32 | 2022 | 3239 | 2.520 |
Why?
|
| Mothers | 18 | 2023 | 569 | 2.500 |
Why?
|
| Weight Gain | 12 | 2023 | 451 | 2.500 |
Why?
|
| Fluorocarbons | 5 | 2023 | 77 | 2.400 |
Why?
|
| Adult | 150 | 2023 | 28937 | 2.400 |
Why?
|
| Colorado | 39 | 2023 | 3845 | 2.380 |
Why?
|
| Age of Onset | 23 | 2022 | 387 | 2.360 |
Why?
|
| Plethysmography | 13 | 2022 | 122 | 2.290 |
Why?
|
| Air Pollution | 8 | 2023 | 185 | 2.290 |
Why?
|
| Air Pollutants | 8 | 2023 | 264 | 2.250 |
Why?
|
| Abdominal Fat | 4 | 2022 | 37 | 2.250 |
Why?
|
| Diabetes Complications | 10 | 2021 | 179 | 2.170 |
Why?
|
| Pregnancy in Diabetics | 9 | 2018 | 38 | 2.130 |
Why?
|
| Environmental Pollutants | 6 | 2023 | 93 | 2.080 |
Why?
|
| DNA Methylation | 13 | 2022 | 362 | 1.980 |
Why?
|
| Linear Models | 23 | 2021 | 797 | 1.940 |
Why?
|
| Food Hypersensitivity | 3 | 2022 | 243 | 1.930 |
Why?
|
| Environmental Exposure | 9 | 2023 | 369 | 1.930 |
Why?
|
| Cholesterol, LDL | 10 | 2022 | 271 | 1.920 |
Why?
|
| Metformin | 17 | 2023 | 276 | 1.880 |
Why?
|
| Hypoglycemic Agents | 24 | 2022 | 618 | 1.880 |
Why?
|
| Triglycerides | 15 | 2023 | 451 | 1.860 |
Why?
|
| Pregnancy Complications | 11 | 2021 | 391 | 1.850 |
Why?
|
| Adipose Tissue | 11 | 2022 | 598 | 1.840 |
Why?
|
| Intra-Abdominal Fat | 5 | 2022 | 75 | 1.790 |
Why?
|
| Feeding Behavior | 10 | 2021 | 505 | 1.780 |
Why?
|
| United States | 88 | 2023 | 11868 | 1.710 |
Why?
|
| Blood Pressure | 16 | 2020 | 1568 | 1.670 |
Why?
|
| Adiponectin | 10 | 2018 | 169 | 1.660 |
Why?
|
| Prediabetic State | 9 | 2023 | 159 | 1.660 |
Why?
|
| Exercise | 14 | 2022 | 1721 | 1.650 |
Why?
|
| Albuminuria | 10 | 2018 | 142 | 1.630 |
Why?
|
| Dyslipidemias | 5 | 2021 | 138 | 1.630 |
Why?
|
| Cannabinoids | 2 | 2023 | 113 | 1.610 |
Why?
|
| Smoking | 7 | 2019 | 1493 | 1.580 |
Why?
|
| Fatty Liver | 4 | 2021 | 236 | 1.580 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2022 | 1759 | 1.580 |
Why?
|
| Epigenesis, Genetic | 12 | 2023 | 425 | 1.530 |
Why?
|
| Insulin-Secreting Cells | 8 | 2017 | 170 | 1.500 |
Why?
|
| Lipids | 14 | 2020 | 529 | 1.430 |
Why?
|
| Incidence | 33 | 2023 | 2281 | 1.420 |
Why?
|
| Overweight | 15 | 2023 | 475 | 1.410 |
Why?
|
| Follow-Up Studies | 29 | 2022 | 4394 | 1.370 |
Why?
|
| Asthma | 7 | 2023 | 1882 | 1.350 |
Why?
|
| Health Behavior | 11 | 2022 | 668 | 1.340 |
Why?
|
| Life Style | 18 | 2022 | 377 | 1.340 |
Why?
|
| Leptin | 8 | 2021 | 205 | 1.330 |
Why?
|
| Child Health | 6 | 2023 | 112 | 1.330 |
Why?
|
| Vitamin D | 5 | 2019 | 338 | 1.300 |
Why?
|
| Energy Metabolism | 6 | 2021 | 837 | 1.290 |
Why?
|
| Islets of Langerhans | 7 | 2021 | 320 | 1.280 |
Why?
|
| Hyperinsulinism | 2 | 2021 | 94 | 1.240 |
Why?
|
| Cannabis | 2 | 2023 | 315 | 1.220 |
Why?
|
| Body Weight | 11 | 2020 | 904 | 1.220 |
Why?
|
| Age Factors | 31 | 2020 | 2877 | 1.190 |
Why?
|
| Indians, North American | 16 | 2022 | 523 | 1.180 |
Why?
|
| Adolescent Behavior | 5 | 2021 | 435 | 1.150 |
Why?
|
| Autoantibodies | 10 | 2022 | 714 | 1.120 |
Why?
|
| Cross-Sectional Studies | 40 | 2023 | 4132 | 1.080 |
Why?
|
| Heart Rate | 7 | 2022 | 753 | 1.080 |
Why?
|
| Hypertension | 12 | 2022 | 1140 | 1.060 |
Why?
|
| Anthropometry | 9 | 2022 | 183 | 1.040 |
Why?
|
| Cognition | 4 | 2023 | 1013 | 1.020 |
Why?
|
| Waist Circumference | 10 | 2019 | 118 | 0.980 |
Why?
|
| Hyperglycemia | 8 | 2021 | 217 | 0.980 |
Why?
|
| Postal Service | 2 | 2016 | 30 | 0.960 |
Why?
|
| Vehicle Emissions | 3 | 2021 | 60 | 0.950 |
Why?
|
| Sex Factors | 17 | 2020 | 1738 | 0.950 |
Why?
|
| Subcutaneous Fat | 4 | 2019 | 80 | 0.930 |
Why?
|
| Pulse Wave Analysis | 12 | 2023 | 163 | 0.920 |
Why?
|
| Cotinine | 2 | 2022 | 65 | 0.900 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2018 | 50 | 0.900 |
Why?
|
| HLA Antigens | 4 | 2014 | 157 | 0.900 |
Why?
|
| Cannabidiol | 1 | 2023 | 52 | 0.890 |
Why?
|
| Insulins | 1 | 2022 | 19 | 0.880 |
Why?
|
| Liver | 3 | 2021 | 1687 | 0.880 |
Why?
|
| Energy Intake | 5 | 2023 | 461 | 0.870 |
Why?
|
| Glutamate Decarboxylase | 5 | 2021 | 50 | 0.850 |
Why?
|
| Registries | 12 | 2021 | 1837 | 0.850 |
Why?
|
| Diabetic Neuropathies | 6 | 2019 | 88 | 0.850 |
Why?
|
| Rhinitis, Allergic | 1 | 2022 | 39 | 0.840 |
Why?
|
| Dietary Carbohydrates | 3 | 2019 | 155 | 0.840 |
Why?
|
| Lipoproteins, HDL | 3 | 2017 | 71 | 0.840 |
Why?
|
| Hallucinogens | 1 | 2023 | 73 | 0.840 |
Why?
|
| Cardiovascular System | 1 | 2023 | 116 | 0.840 |
Why?
|
| Inflammation | 7 | 2022 | 2210 | 0.840 |
Why?
|
| Vitamins | 4 | 2023 | 150 | 0.820 |
Why?
|
| Polymorphism, Genetic | 6 | 2012 | 506 | 0.820 |
Why?
|
| Diet Surveys | 6 | 2021 | 68 | 0.810 |
Why?
|
| Eczema | 1 | 2022 | 79 | 0.810 |
Why?
|
| Metabolic Diseases | 2 | 2021 | 100 | 0.810 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2019 | 457 | 0.800 |
Why?
|
| Health Status | 3 | 2023 | 738 | 0.800 |
Why?
|
| Mitochondria, Muscle | 2 | 2021 | 91 | 0.780 |
Why?
|
| Diabetic Retinopathy | 5 | 2023 | 109 | 0.780 |
Why?
|
| Motor Activity | 6 | 2015 | 666 | 0.770 |
Why?
|
| Case-Control Studies | 23 | 2022 | 2840 | 0.770 |
Why?
|
| Chemokines | 1 | 2021 | 184 | 0.760 |
Why?
|
| Logistic Models | 18 | 2023 | 1806 | 0.760 |
Why?
|
| Child Welfare | 2 | 2012 | 117 | 0.760 |
Why?
|
| Transition to Adult Care | 2 | 2018 | 48 | 0.750 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 2 | 2016 | 7 | 0.740 |
Why?
|
| C-Peptide | 7 | 2021 | 58 | 0.730 |
Why?
|
| Gestational Age | 10 | 2023 | 631 | 0.730 |
Why?
|
| Calcinosis | 6 | 2011 | 235 | 0.730 |
Why?
|
| Vitamin D Deficiency | 2 | 2019 | 153 | 0.730 |
Why?
|
| Premature Birth | 4 | 2022 | 223 | 0.730 |
Why?
|
| Glucose Intolerance | 10 | 2017 | 99 | 0.720 |
Why?
|
| Comorbidity | 6 | 2023 | 1524 | 0.720 |
Why?
|
| Puberty, Precocious | 1 | 2018 | 12 | 0.710 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2020 | 94 | 0.710 |
Why?
|
| Community-Institutional Relations | 2 | 2016 | 92 | 0.700 |
Why?
|
| Maternal Health | 3 | 2019 | 35 | 0.690 |
Why?
|
| Disease Progression | 15 | 2021 | 2142 | 0.670 |
Why?
|
| Adenosine Diphosphate | 2 | 2021 | 81 | 0.670 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2019 | 103 | 0.660 |
Why?
|
| Body Height | 6 | 2018 | 158 | 0.660 |
Why?
|
| Patient Selection | 3 | 2016 | 663 | 0.650 |
Why?
|
| Vaccines | 1 | 2022 | 340 | 0.650 |
Why?
|
| Body Fluid Compartments | 1 | 2017 | 6 | 0.640 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 285 | 0.640 |
Why?
|
| Niacin | 1 | 2017 | 19 | 0.640 |
Why?
|
| Fasting | 11 | 2023 | 232 | 0.640 |
Why?
|
| Health Surveys | 4 | 2021 | 431 | 0.630 |
Why?
|
| Metabolome | 1 | 2020 | 290 | 0.630 |
Why?
|
| Alkanesulfonic Acids | 3 | 2023 | 29 | 0.620 |
Why?
|
| Multivariate Analysis | 14 | 2017 | 1425 | 0.620 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 3 | 2014 | 8 | 0.620 |
Why?
|
| Socioeconomic Factors | 15 | 2022 | 1050 | 0.610 |
Why?
|
| Sex Characteristics | 2 | 2020 | 626 | 0.590 |
Why?
|
| Autonomic Nervous System | 2 | 2013 | 61 | 0.590 |
Why?
|
| Cholesterol, HDL | 5 | 2021 | 156 | 0.590 |
Why?
|
| Cytokines | 2 | 2021 | 1598 | 0.590 |
Why?
|
| Particulate Matter | 7 | 2022 | 202 | 0.590 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2016 | 12 | 0.580 |
Why?
|
| Regression Analysis | 9 | 2019 | 934 | 0.580 |
Why?
|
| Coronary Artery Disease | 7 | 2017 | 561 | 0.580 |
Why?
|
| Fetal Diseases | 1 | 2017 | 146 | 0.580 |
Why?
|
| Predictive Value of Tests | 13 | 2021 | 1750 | 0.570 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 31 | 0.570 |
Why?
|
| Glucose | 9 | 2023 | 824 | 0.570 |
Why?
|
| Puberty | 5 | 2022 | 129 | 0.560 |
Why?
|
| Child of Impaired Parents | 2 | 2015 | 41 | 0.560 |
Why?
|
| Prenatal Care | 1 | 2017 | 177 | 0.560 |
Why?
|
| Epidemiologic Studies | 2 | 2018 | 54 | 0.560 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 232 | 0.560 |
Why?
|
| Mental Health | 2 | 2022 | 477 | 0.560 |
Why?
|
| Surveys and Questionnaires | 19 | 2019 | 4452 | 0.560 |
Why?
|
| Dietary Proteins | 1 | 2016 | 113 | 0.550 |
Why?
|
| Patient Compliance | 4 | 2016 | 520 | 0.550 |
Why?
|
| Apolipoproteins B | 5 | 2012 | 36 | 0.540 |
Why?
|
| Dietary Fats | 3 | 2016 | 316 | 0.530 |
Why?
|
| Smoking Cessation | 1 | 2018 | 348 | 0.530 |
Why?
|
| Electronic Health Records | 5 | 2021 | 641 | 0.530 |
Why?
|
| Risk Assessment | 11 | 2021 | 2934 | 0.530 |
Why?
|
| Television | 3 | 2015 | 66 | 0.530 |
Why?
|
| Pregnancy Outcome | 4 | 2019 | 268 | 0.520 |
Why?
|
| Mental Recall | 3 | 2021 | 192 | 0.520 |
Why?
|
| Dietary Supplements | 3 | 2023 | 426 | 0.520 |
Why?
|
| Vaccination | 1 | 2022 | 1072 | 0.520 |
Why?
|
| Creatinine | 4 | 2016 | 427 | 0.520 |
Why?
|
| Risk Reduction Behavior | 3 | 2017 | 197 | 0.510 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 2 | 2011 | 11 | 0.510 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2015 | 113 | 0.510 |
Why?
|
| Metabolic Syndrome | 5 | 2021 | 369 | 0.510 |
Why?
|
| Retrospective Studies | 18 | 2023 | 11378 | 0.510 |
Why?
|
| Odds Ratio | 10 | 2023 | 932 | 0.510 |
Why?
|
| Homeostasis | 4 | 2021 | 480 | 0.510 |
Why?
|
| Health Promotion | 4 | 2017 | 639 | 0.510 |
Why?
|
| Physical Fitness | 2 | 2012 | 182 | 0.500 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2014 | 31 | 0.490 |
Why?
|
| Social Class | 5 | 2021 | 210 | 0.490 |
Why?
|
| Autoimmunity | 6 | 2021 | 375 | 0.490 |
Why?
|
| Muscle Cells | 2 | 2017 | 38 | 0.480 |
Why?
|
| Lipid Metabolism | 5 | 2017 | 434 | 0.470 |
Why?
|
| Glucose Tolerance Test | 8 | 2021 | 295 | 0.470 |
Why?
|
| Ohio | 6 | 2015 | 125 | 0.470 |
Why?
|
| Adolescent Development | 1 | 2013 | 83 | 0.460 |
Why?
|
| Prognosis | 6 | 2021 | 3150 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2021 | 2884 | 0.450 |
Why?
|
| Nutrition Policy | 4 | 2023 | 57 | 0.440 |
Why?
|
| Fatty Acids, Nonesterified | 4 | 2022 | 161 | 0.440 |
Why?
|
| Carotid Arteries | 1 | 2013 | 167 | 0.440 |
Why?
|
| Femoral Artery | 1 | 2013 | 170 | 0.440 |
Why?
|
| Data Collection | 4 | 2022 | 622 | 0.440 |
Why?
|
| Time Factors | 13 | 2022 | 6271 | 0.430 |
Why?
|
| Pandemics | 7 | 2023 | 1095 | 0.430 |
Why?
|
| Food Supply | 4 | 2023 | 50 | 0.430 |
Why?
|
| Proportional Hazards Models | 11 | 2022 | 1054 | 0.430 |
Why?
|
| Diabetic Nephropathies | 6 | 2020 | 219 | 0.430 |
Why?
|
| Arteries | 2 | 2010 | 213 | 0.420 |
Why?
|
| Genome-Wide Association Study | 8 | 2023 | 879 | 0.410 |
Why?
|
| Maternal Age | 4 | 2021 | 96 | 0.410 |
Why?
|
| Sugars | 2 | 2023 | 24 | 0.410 |
Why?
|
| Nutrition Assessment | 2 | 2021 | 68 | 0.410 |
Why?
|
| Down-Regulation | 1 | 2013 | 538 | 0.410 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2023 | 25 | 0.410 |
Why?
|
| Risk | 7 | 2018 | 820 | 0.410 |
Why?
|
| DNA Helicases | 1 | 2012 | 98 | 0.410 |
Why?
|
| Self Concept | 1 | 2012 | 202 | 0.400 |
Why?
|
| Vegetables | 4 | 2020 | 110 | 0.400 |
Why?
|
| Cesarean Section | 1 | 2012 | 120 | 0.400 |
Why?
|
| Geographic Information Systems | 2 | 2012 | 39 | 0.390 |
Why?
|
| Population Surveillance | 6 | 2016 | 396 | 0.390 |
Why?
|
| Respiratory Sounds | 2 | 2021 | 109 | 0.390 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 283 | 0.390 |
Why?
|
| Phthalic Acids | 2 | 2022 | 23 | 0.390 |
Why?
|
| Residence Characteristics | 5 | 2023 | 273 | 0.390 |
Why?
|
| Autistic Disorder | 2 | 2022 | 140 | 0.390 |
Why?
|
| Self Report | 4 | 2021 | 677 | 0.380 |
Why?
|
| Alleles | 6 | 2021 | 571 | 0.380 |
Why?
|
| Pesticides | 2 | 2022 | 65 | 0.380 |
Why?
|
| Middle Aged | 39 | 2023 | 26115 | 0.380 |
Why?
|
| Eating | 6 | 2023 | 348 | 0.370 |
Why?
|
| Autism Spectrum Disorder | 3 | 2022 | 249 | 0.370 |
Why?
|
| Fetal Development | 4 | 2019 | 186 | 0.370 |
Why?
|
| Calcium | 6 | 2023 | 1022 | 0.370 |
Why?
|
| Lipoproteins | 2 | 2016 | 134 | 0.370 |
Why?
|
| Minority Groups | 6 | 2023 | 208 | 0.370 |
Why?
|
| Diet, Mediterranean | 2 | 2022 | 13 | 0.370 |
Why?
|
| Gene-Environment Interaction | 2 | 2021 | 162 | 0.360 |
Why?
|
| Hypoglycemia | 2 | 2022 | 203 | 0.350 |
Why?
|
| Public Health | 1 | 2013 | 442 | 0.350 |
Why?
|
| Testosterone | 3 | 2021 | 310 | 0.350 |
Why?
|
| Blood Glucose Self-Monitoring | 5 | 2022 | 133 | 0.340 |
Why?
|
| Placenta | 3 | 2022 | 398 | 0.340 |
Why?
|
| Adipogenesis | 3 | 2023 | 44 | 0.340 |
Why?
|
| Fatty Acids | 3 | 2021 | 376 | 0.330 |
Why?
|
| Micronutrients | 2 | 2021 | 73 | 0.330 |
Why?
|
| Hunger | 2 | 2019 | 49 | 0.330 |
Why?
|
| South Carolina | 4 | 2012 | 16 | 0.320 |
Why?
|
| Mass Screening | 5 | 2020 | 928 | 0.320 |
Why?
|
| American Heart Association | 2 | 2023 | 302 | 0.320 |
Why?
|
| Analysis of Variance | 5 | 2018 | 1311 | 0.310 |
Why?
|
| Weight Loss | 5 | 2021 | 674 | 0.310 |
Why?
|
| Cost of Illness | 1 | 2009 | 272 | 0.310 |
Why?
|
| C-Reactive Protein | 5 | 2019 | 310 | 0.310 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 738 | 0.300 |
Why?
|
| Treatment Outcome | 12 | 2020 | 8878 | 0.300 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2017 | 48 | 0.300 |
Why?
|
| Diet Records | 4 | 2021 | 69 | 0.300 |
Why?
|
| Body Size | 2 | 2020 | 92 | 0.300 |
Why?
|
| Microvessels | 2 | 2019 | 71 | 0.300 |
Why?
|
| Weight Reduction Programs | 2 | 2017 | 88 | 0.300 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2019 | 94 | 0.290 |
Why?
|
| Causality | 2 | 2020 | 110 | 0.290 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2017 | 10 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2023 | 1471 | 0.280 |
Why?
|
| Coronary Disease | 3 | 2007 | 335 | 0.280 |
Why?
|
| Folic Acid | 4 | 2023 | 135 | 0.280 |
Why?
|
| Retinal Diseases | 2 | 2023 | 63 | 0.270 |
Why?
|
| Protective Factors | 3 | 2021 | 93 | 0.270 |
Why?
|
| Internet | 1 | 2010 | 612 | 0.270 |
Why?
|
| Fetal Macrosomia | 2 | 2018 | 36 | 0.260 |
Why?
|
| Insurance, Health | 3 | 2023 | 244 | 0.260 |
Why?
|
| Beverages | 2 | 2015 | 62 | 0.260 |
Why?
|
| Parents | 6 | 2022 | 994 | 0.260 |
Why?
|
| Health | 2 | 2015 | 68 | 0.260 |
Why?
|
| Menarche | 2 | 2018 | 42 | 0.260 |
Why?
|
| Parturition | 2 | 2022 | 40 | 0.250 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2021 | 41 | 0.250 |
Why?
|
| Algorithms | 5 | 2021 | 1374 | 0.240 |
Why?
|
| HLA-DQ beta-Chains | 3 | 2019 | 31 | 0.240 |
Why?
|
| Pregnant Women | 3 | 2023 | 104 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 1738 | 0.240 |
Why?
|
| HLA-DRB1 Chains | 3 | 2019 | 70 | 0.240 |
Why?
|
| Vitamin A | 1 | 2023 | 45 | 0.240 |
Why?
|
| Food Assistance | 1 | 2023 | 14 | 0.230 |
Why?
|
| Infant, Low Birth Weight | 3 | 2012 | 111 | 0.230 |
Why?
|
| India | 2 | 2020 | 137 | 0.230 |
Why?
|
| Cholesterol | 4 | 2023 | 333 | 0.230 |
Why?
|
| Nutritional Status | 4 | 2018 | 267 | 0.230 |
Why?
|
| Population Health | 1 | 2023 | 42 | 0.230 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2013 | 84 | 0.220 |
Why?
|
| Reference Values | 5 | 2012 | 719 | 0.220 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 9 | 0.220 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2022 | 15 | 0.220 |
Why?
|
| Membrane Proteins | 3 | 2021 | 788 | 0.220 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2022 | 21 | 0.220 |
Why?
|
| Pregnancy Proteins | 1 | 2022 | 25 | 0.220 |
Why?
|
| Umbilical Cord | 3 | 2017 | 69 | 0.220 |
Why?
|
| Starch | 1 | 2022 | 23 | 0.220 |
Why?
|
| Cortisone | 1 | 2021 | 10 | 0.210 |
Why?
|
| Patient Education as Topic | 4 | 2018 | 628 | 0.210 |
Why?
|
| Ozone | 1 | 2022 | 102 | 0.210 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 98 | 0.210 |
Why?
|
| Pregnanolone | 1 | 2021 | 21 | 0.210 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2018 | 472 | 0.210 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2021 | 16 | 0.210 |
Why?
|
| Tobacco | 1 | 2022 | 154 | 0.210 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2019 | 24 | 0.210 |
Why?
|
| Arizona | 6 | 2000 | 58 | 0.210 |
Why?
|
| Health Services, Indigenous | 1 | 2021 | 28 | 0.210 |
Why?
|
| Phenotype | 8 | 2022 | 2513 | 0.210 |
Why?
|
| Klinefelter Syndrome | 1 | 2021 | 35 | 0.210 |
Why?
|
| Macular Degeneration | 1 | 2023 | 121 | 0.210 |
Why?
|
| Allostasis | 1 | 2021 | 14 | 0.210 |
Why?
|
| Immunization Schedule | 1 | 2022 | 174 | 0.210 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2021 | 6 | 0.210 |
Why?
|
| Endotoxins | 1 | 2022 | 230 | 0.210 |
Why?
|
| Muscle, Skeletal | 3 | 2021 | 1498 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2021 | 16 | 0.200 |
Why?
|
| Glycation End Products, Advanced | 1 | 2021 | 68 | 0.200 |
Why?
|
| Lipase | 1 | 2021 | 51 | 0.200 |
Why?
|
| Depression, Postpartum | 1 | 2022 | 90 | 0.200 |
Why?
|
| Food | 1 | 2022 | 157 | 0.200 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 42 | 0.200 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 641 | 0.200 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 1 | 0.200 |
Why?
|
| Quality of Life | 7 | 2022 | 2221 | 0.200 |
Why?
|
| Epidemiological Monitoring | 1 | 2021 | 46 | 0.200 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2021 | 106 | 0.200 |
Why?
|
| Phospholipids | 2 | 2019 | 174 | 0.200 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 77 | 0.200 |
Why?
|
| Slovenia | 1 | 2020 | 1 | 0.200 |
Why?
|
| Age Distribution | 2 | 2019 | 352 | 0.200 |
Why?
|
| Fibrinogen | 4 | 2019 | 127 | 0.200 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 443 | 0.200 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2018 | 58 | 0.200 |
Why?
|
| Denmark | 1 | 2020 | 37 | 0.200 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 143 | 0.190 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2020 | 140 | 0.190 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 383 | 0.190 |
Why?
|
| Germany | 1 | 2020 | 57 | 0.190 |
Why?
|
| Metabolomics | 3 | 2020 | 509 | 0.190 |
Why?
|
| Genetic Markers | 1 | 2021 | 297 | 0.190 |
Why?
|
| Nervous System Diseases | 1 | 2023 | 237 | 0.190 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2012 | 35 | 0.190 |
Why?
|
| Immunization | 1 | 2022 | 347 | 0.190 |
Why?
|
| Brachial Artery | 2 | 2013 | 184 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 217 | 0.190 |
Why?
|
| Progesterone | 1 | 2021 | 217 | 0.190 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 260 | 0.190 |
Why?
|
| Infant, Premature | 2 | 2023 | 451 | 0.190 |
Why?
|
| Thioctic Acid | 1 | 1999 | 10 | 0.180 |
Why?
|
| Research Design | 2 | 2023 | 907 | 0.180 |
Why?
|
| Child Behavior | 1 | 2021 | 199 | 0.180 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 8 | 0.180 |
Why?
|
| Ventricular Remodeling | 1 | 2021 | 220 | 0.180 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 161 | 0.180 |
Why?
|
| HLA-D Antigens | 1 | 2019 | 18 | 0.180 |
Why?
|
| Dehydroepiandrosterone | 1 | 2019 | 52 | 0.180 |
Why?
|
| Genetic Variation | 2 | 2021 | 703 | 0.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2021 | 455 | 0.180 |
Why?
|
| Mutation | 3 | 2022 | 2854 | 0.180 |
Why?
|
| Bayes Theorem | 4 | 2023 | 301 | 0.180 |
Why?
|
| Demography | 1 | 2020 | 256 | 0.180 |
Why?
|
| Societies, Medical | 3 | 2018 | 693 | 0.180 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 742 | 0.180 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2018 | 4 | 0.180 |
Why?
|
| Luteinizing Hormone | 1 | 2019 | 153 | 0.180 |
Why?
|
| Hydrocortisone | 1 | 2021 | 299 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2021 | 244 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 560 | 0.180 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 2663 | 0.170 |
Why?
|
| Pediatrics | 3 | 2018 | 868 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 215 | 0.170 |
Why?
|
| Sexual Maturation | 1 | 2018 | 47 | 0.170 |
Why?
|
| Exome | 1 | 2019 | 134 | 0.170 |
Why?
|
| Guideline Adherence | 2 | 2014 | 499 | 0.170 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 322 | 0.170 |
Why?
|
| Echocardiography | 1 | 2021 | 580 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2023 | 642 | 0.170 |
Why?
|
| Apolipoproteins A | 2 | 1995 | 13 | 0.170 |
Why?
|
| Self Efficacy | 2 | 2018 | 333 | 0.170 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 383 | 0.170 |
Why?
|
| Epidemiologic Research Design | 1 | 2018 | 33 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 301 | 0.160 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2018 | 41 | 0.160 |
Why?
|
| PPAR gamma | 2 | 2016 | 166 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 486 | 0.160 |
Why?
|
| Fear | 1 | 2020 | 295 | 0.160 |
Why?
|
| Genome, Human | 1 | 2019 | 233 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 2017 | 8 | 0.160 |
Why?
|
| Glucokinase | 2 | 2017 | 10 | 0.160 |
Why?
|
| Endocrine Disruptors | 1 | 2018 | 35 | 0.160 |
Why?
|
| Trans Fatty Acids | 1 | 2017 | 6 | 0.160 |
Why?
|
| Epigenomics | 1 | 2018 | 77 | 0.160 |
Why?
|
| Phosphorus Isotopes | 1 | 2017 | 5 | 0.160 |
Why?
|
| Phenols | 1 | 2018 | 64 | 0.160 |
Why?
|
| Granuloma | 1 | 2017 | 69 | 0.160 |
Why?
|
| Skinfold Thickness | 2 | 2020 | 49 | 0.160 |
Why?
|
| Brain | 2 | 2020 | 2520 | 0.160 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2018 | 84 | 0.160 |
Why?
|
| Cystatin C | 1 | 2017 | 47 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 386 | 0.160 |
Why?
|
| Caprylates | 1 | 2017 | 19 | 0.160 |
Why?
|
| Awards and Prizes | 1 | 2018 | 52 | 0.160 |
Why?
|
| Satiation | 1 | 2017 | 24 | 0.160 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2017 | 46 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2018 | 157 | 0.160 |
Why?
|
| Rheumatoid Factor | 1 | 2018 | 146 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2019 | 227 | 0.160 |
Why?
|
| Genomics | 1 | 2021 | 491 | 0.160 |
Why?
|
| Needs Assessment | 3 | 2016 | 320 | 0.150 |
Why?
|
| Feeding and Eating Disorders | 1 | 2019 | 124 | 0.150 |
Why?
|
| Leisure Activities | 1 | 2016 | 28 | 0.150 |
Why?
|
| Language | 1 | 2019 | 231 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 153 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2018 | 256 | 0.150 |
Why?
|
| Gene Expression | 2 | 2021 | 1293 | 0.150 |
Why?
|
| Endocrinology | 1 | 2018 | 80 | 0.150 |
Why?
|
| Precision Medicine | 2 | 2023 | 272 | 0.150 |
Why?
|
| Reward | 1 | 2019 | 215 | 0.150 |
Why?
|
| Arsenic | 1 | 2016 | 30 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 1093 | 0.150 |
Why?
|
| Mexico | 2 | 2011 | 126 | 0.150 |
Why?
|
| Oxidative Phosphorylation | 1 | 2017 | 150 | 0.150 |
Why?
|
| Dietary Fiber | 2 | 2014 | 39 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2019 | 342 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2018 | 202 | 0.150 |
Why?
|
| Nutrition Surveys | 4 | 2019 | 210 | 0.150 |
Why?
|
| Exercise Therapy | 2 | 2017 | 370 | 0.150 |
Why?
|
| Niacinamide | 1 | 2016 | 63 | 0.150 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2017 | 117 | 0.150 |
Why?
|
| Haplotypes | 2 | 2019 | 283 | 0.150 |
Why?
|
| Vitamin B 12 | 1 | 2016 | 103 | 0.150 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 130 | 0.140 |
Why?
|
| Feces | 1 | 2018 | 333 | 0.140 |
Why?
|
| Microbiota | 2 | 2019 | 537 | 0.140 |
Why?
|
| CpG Islands | 3 | 2021 | 83 | 0.140 |
Why?
|
| Emigrants and Immigrants | 3 | 2012 | 86 | 0.140 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 81 | 0.140 |
Why?
|
| Bacteria | 2 | 2018 | 631 | 0.140 |
Why?
|
| Calcium, Dietary | 3 | 2023 | 52 | 0.140 |
Why?
|
| Choristoma | 1 | 2015 | 25 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 202 | 0.140 |
Why?
|
| Nutrition Therapy | 2 | 2013 | 29 | 0.140 |
Why?
|
| Apolipoprotein A-I | 1 | 1995 | 26 | 0.140 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2015 | 8 | 0.140 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2015 | 13 | 0.140 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 78 | 0.140 |
Why?
|
| Antioxidants | 1 | 1999 | 547 | 0.140 |
Why?
|
| Sulfonylurea Receptors | 2 | 2012 | 9 | 0.140 |
Why?
|
| Genotype | 6 | 2023 | 1443 | 0.140 |
Why?
|
| Phylogeny | 1 | 2018 | 697 | 0.140 |
Why?
|
| Resilience, Psychological | 1 | 2016 | 96 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 167 | 0.130 |
Why?
|
| Family | 1 | 2018 | 474 | 0.130 |
Why?
|
| Pregnancy Trimesters | 1 | 2014 | 9 | 0.130 |
Why?
|
| Cluster Analysis | 3 | 2013 | 446 | 0.130 |
Why?
|
| Interleukin-6 | 3 | 2019 | 619 | 0.130 |
Why?
|
| Computers | 1 | 2014 | 62 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2019 | 530 | 0.130 |
Why?
|
| Muscle Strength | 1 | 2017 | 277 | 0.130 |
Why?
|
| Family Health | 1 | 2015 | 148 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 1111 | 0.130 |
Why?
|
| Carbonated Beverages | 2 | 2011 | 19 | 0.130 |
Why?
|
| Executive Function | 1 | 2019 | 378 | 0.130 |
Why?
|
| Rural Population | 1 | 2018 | 436 | 0.130 |
Why?
|
| beta Catenin | 1 | 2015 | 187 | 0.130 |
Why?
|
| Vasculitis | 1 | 2014 | 68 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 1062 | 0.120 |
Why?
|
| Proteinuria | 1 | 1994 | 84 | 0.120 |
Why?
|
| Nutritional Requirements | 2 | 2021 | 78 | 0.120 |
Why?
|
| Cation Transport Proteins | 1 | 2014 | 47 | 0.120 |
Why?
|
| SEER Program | 2 | 2011 | 174 | 0.120 |
Why?
|
| Muscle Development | 3 | 2021 | 99 | 0.120 |
Why?
|
| Autoimmune Diseases | 2 | 2017 | 277 | 0.120 |
Why?
|
| Pilot Projects | 5 | 2017 | 1271 | 0.120 |
Why?
|
| DNA | 1 | 2019 | 1068 | 0.120 |
Why?
|
| Transients and Migrants | 1 | 2012 | 18 | 0.110 |
Why?
|
| Medicare | 2 | 2023 | 694 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2015 | 247 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1116 | 0.110 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2014 | 129 | 0.110 |
Why?
|
| Insulin, Regular, Human | 2 | 2022 | 8 | 0.110 |
Why?
|
| Managed Care Programs | 1 | 2013 | 154 | 0.110 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 738 | 0.110 |
Why?
|
| Body Constitution | 1 | 2012 | 49 | 0.110 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2015 | 134 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 254 | 0.110 |
Why?
|
| HLA-DP beta-Chains | 1 | 2012 | 58 | 0.110 |
Why?
|
| Europe | 2 | 2011 | 293 | 0.110 |
Why?
|
| Romania | 4 | 1995 | 16 | 0.110 |
Why?
|
| Statistics, Nonparametric | 4 | 2017 | 403 | 0.110 |
Why?
|
| Mammary Glands, Human | 1 | 2012 | 57 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2012 | 66 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2013 | 137 | 0.110 |
Why?
|
| Proinsulin | 1 | 2011 | 16 | 0.110 |
Why?
|
| Aged | 8 | 2023 | 18789 | 0.110 |
Why?
|
| Thinness | 1 | 2012 | 89 | 0.110 |
Why?
|
| Coronary Vessels | 3 | 2017 | 216 | 0.110 |
Why?
|
| Insulin Antibodies | 1 | 2011 | 26 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2022 | 3956 | 0.100 |
Why?
|
| Mexican Americans | 1 | 2012 | 76 | 0.100 |
Why?
|
| Beryllium | 1 | 2012 | 140 | 0.100 |
Why?
|
| Morphogenesis | 1 | 2012 | 161 | 0.100 |
Why?
|
| Amine Oxidase (Copper-Containing) | 1 | 2010 | 5 | 0.100 |
Why?
|
| Lactation | 1 | 2012 | 160 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2017 | 675 | 0.100 |
Why?
|
| HLA-DR Antigens | 2 | 2009 | 132 | 0.100 |
Why?
|
| Diet, Diabetic | 1 | 2011 | 29 | 0.100 |
Why?
|
| Chronic Disease | 5 | 2022 | 1559 | 0.100 |
Why?
|
| E-Selectin | 1 | 2010 | 34 | 0.100 |
Why?
|
| Self Care | 1 | 2013 | 317 | 0.100 |
Why?
|
| Photography | 2 | 2021 | 79 | 0.100 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2011 | 33 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 819 | 0.100 |
Why?
|
| Voluntary Health Agencies | 2 | 2000 | 6 | 0.100 |
Why?
|
| Sweetening Agents | 1 | 2011 | 50 | 0.100 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 51 | 0.100 |
Why?
|
| Berylliosis | 1 | 2012 | 164 | 0.100 |
Why?
|
| Metabolic Equivalent | 1 | 2010 | 3 | 0.100 |
Why?
|
| Milk, Human | 1 | 2012 | 145 | 0.100 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 276 | 0.100 |
Why?
|
| Topography, Medical | 1 | 2010 | 9 | 0.100 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 917 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 676 | 0.100 |
Why?
|
| Glucose Clamp Technique | 1 | 2010 | 166 | 0.100 |
Why?
|
| Glycosuria | 1 | 2009 | 4 | 0.100 |
Why?
|
| Video Games | 1 | 2010 | 24 | 0.090 |
Why?
|
| Pulsatile Flow | 1 | 2010 | 43 | 0.090 |
Why?
|
| World Health Organization | 2 | 2000 | 108 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 150 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2010 | 82 | 0.090 |
Why?
|
| Depression | 2 | 2022 | 1134 | 0.090 |
Why?
|
| Stochastic Processes | 1 | 2009 | 64 | 0.090 |
Why?
|
| Exercise Test | 1 | 2012 | 597 | 0.090 |
Why?
|
| Elasticity | 1 | 2010 | 183 | 0.090 |
Why?
|
| Mortality | 1 | 2011 | 303 | 0.090 |
Why?
|
| Arm | 1 | 2010 | 97 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2017 | 668 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2022 | 282 | 0.090 |
Why?
|
| Carbon | 2 | 2021 | 158 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2023 | 1285 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 837 | 0.090 |
Why?
|
| Blood Flow Velocity | 1 | 2010 | 278 | 0.090 |
Why?
|
| Limit of Detection | 2 | 2021 | 49 | 0.090 |
Why?
|
| Menopause | 1 | 2011 | 252 | 0.090 |
Why?
|
| Genetic Carrier Screening | 1 | 2008 | 24 | 0.090 |
Why?
|
| Health Personnel | 1 | 2013 | 502 | 0.080 |
Why?
|
| Reproductive History | 1 | 2008 | 9 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 521 | 0.080 |
Why?
|
| Pregnancy in Adolescence | 1 | 2008 | 46 | 0.080 |
Why?
|
| HLA-DQ Antigens | 1 | 2008 | 66 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 850 | 0.080 |
Why?
|
| Leg | 1 | 2010 | 254 | 0.080 |
Why?
|
| Receptors, Drug | 1 | 2007 | 16 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2011 | 582 | 0.080 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 122 | 0.080 |
Why?
|
| Forecasting | 1 | 2009 | 351 | 0.080 |
Why?
|
| Contraception | 1 | 2008 | 98 | 0.080 |
Why?
|
| Animals | 5 | 2022 | 28705 | 0.080 |
Why?
|
| Vascular Diseases | 1 | 2010 | 227 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2011 | 566 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2011 | 1043 | 0.070 |
Why?
|
| Oxidation-Reduction | 2 | 2021 | 881 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2021 | 1398 | 0.070 |
Why?
|
| Potassium Channels | 1 | 2007 | 125 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 121 | 0.070 |
Why?
|
| Educational Status | 1 | 2008 | 368 | 0.070 |
Why?
|
| Diet, Reducing | 2 | 2017 | 84 | 0.070 |
Why?
|
| Global Health | 2 | 2021 | 314 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2008 | 541 | 0.070 |
Why?
|
| Homeodomain Proteins | 2 | 2021 | 388 | 0.070 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 24 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 6275 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2019 | 320 | 0.070 |
Why?
|
| Sleep | 2 | 2022 | 745 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 366 | 0.070 |
Why?
|
| Cause of Death | 2 | 2021 | 375 | 0.070 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 99 | 0.070 |
Why?
|
| Lysine | 1 | 2007 | 216 | 0.070 |
Why?
|
| Poverty | 2 | 2023 | 408 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2006 | 277 | 0.070 |
Why?
|
| Autoantigens | 1 | 2006 | 165 | 0.070 |
Why?
|
| Abdominal Wall | 1 | 2004 | 23 | 0.070 |
Why?
|
| Patient Participation | 1 | 2008 | 345 | 0.070 |
Why?
|
| Mitochondria | 2 | 2021 | 719 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2015 | 215 | 0.060 |
Why?
|
| Alkanesulfonates | 1 | 2023 | 4 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2023 | 116 | 0.060 |
Why?
|
| Carboxylic Acids | 1 | 2023 | 26 | 0.060 |
Why?
|
| Environmental Health | 1 | 2023 | 33 | 0.060 |
Why?
|
| Remission Induction | 1 | 2004 | 245 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 329 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2015 | 109 | 0.060 |
Why?
|
| Environment Design | 1 | 2023 | 17 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2019 | 351 | 0.060 |
Why?
|
| Magnesium | 1 | 2023 | 136 | 0.060 |
Why?
|
| Gender Identity | 1 | 2023 | 88 | 0.060 |
Why?
|
| Sample Size | 1 | 2023 | 114 | 0.060 |
Why?
|
| Ascorbic Acid | 1 | 2023 | 92 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2004 | 2215 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1255 | 0.060 |
Why?
|
| Insulin Infusion Systems | 1 | 2022 | 40 | 0.060 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2022 | 3 | 0.060 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 67 | 0.060 |
Why?
|
| Africa, Northern | 1 | 2021 | 3 | 0.060 |
Why?
|
| Tobacco Smoking | 1 | 2022 | 19 | 0.060 |
Why?
|
| Middle East | 1 | 2021 | 10 | 0.050 |
Why?
|
| Cytosine | 1 | 2022 | 38 | 0.050 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 768 | 0.050 |
Why?
|
| Sodium | 1 | 2023 | 197 | 0.050 |
Why?
|
| Adipocytes | 1 | 2023 | 173 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2012 | 204 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2023 | 129 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2004 | 314 | 0.050 |
Why?
|
| Guanine | 1 | 2022 | 70 | 0.050 |
Why?
|
| Phosphocreatine | 1 | 2021 | 37 | 0.050 |
Why?
|
| Adolescent Health | 1 | 2022 | 28 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 278 | 0.050 |
Why?
|
| Metabolic Flux Analysis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Isomerism | 1 | 2021 | 49 | 0.050 |
Why?
|
| Iron | 1 | 2023 | 204 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2017 | 260 | 0.050 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2021 | 7 | 0.050 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2021 | 6 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 424 | 0.050 |
Why?
|
| Phosphates | 1 | 2022 | 151 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 2013 | 65 | 0.050 |
Why?
|
| Diastole | 1 | 2021 | 153 | 0.050 |
Why?
|
| Protein Interaction Mapping | 1 | 2021 | 81 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 209 | 0.050 |
Why?
|
| Maternal Inheritance | 1 | 2020 | 12 | 0.050 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 28 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 140 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2021 | 116 | 0.050 |
Why?
|
| Fathers | 1 | 2000 | 38 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2008 | 312 | 0.050 |
Why?
|
| Hospitalization | 1 | 2008 | 1589 | 0.050 |
Why?
|
| Schools | 1 | 2023 | 374 | 0.050 |
Why?
|
| Western World | 1 | 2019 | 3 | 0.050 |
Why?
|
| Community Health Services | 1 | 2021 | 192 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 84 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 451 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 2683 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 62 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 375 | 0.050 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2019 | 7 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 369 | 0.040 |
Why?
|
| Hyperphagia | 1 | 2019 | 29 | 0.040 |
Why?
|
| Software | 1 | 2023 | 455 | 0.040 |
Why?
|
| Norway | 1 | 2018 | 30 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 643 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 1646 | 0.040 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 274 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 995 | 0.040 |
Why?
|
| Walking | 1 | 2023 | 419 | 0.040 |
Why?
|
| Health Services Research | 1 | 2021 | 359 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2023 | 451 | 0.040 |
Why?
|
| Pregnancy Trimester, First | 1 | 2018 | 97 | 0.040 |
Why?
|
| Environmental Pollution | 1 | 2018 | 17 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 348 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 159 | 0.040 |
Why?
|
| Bifidobacterium | 1 | 2017 | 15 | 0.040 |
Why?
|
| Fruit | 2 | 2011 | 113 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 4 | 0.040 |
Why?
|
| Electron Transport | 1 | 2017 | 87 | 0.040 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2017 | 38 | 0.040 |
Why?
|
| Genes, rRNA | 1 | 2017 | 37 | 0.040 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 55 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 235 | 0.040 |
Why?
|
| Carnitine | 1 | 2017 | 65 | 0.040 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2017 | 42 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2008 | 1717 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 202 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 152 | 0.040 |
Why?
|
| Mitochondrial Diseases | 1 | 2017 | 65 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 601 | 0.040 |
Why?
|
| ROC Curve | 2 | 2013 | 444 | 0.040 |
Why?
|
| Birth Rate | 1 | 2016 | 17 | 0.040 |
Why?
|
| Sirtuin 1 | 1 | 2016 | 31 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 474 | 0.040 |
Why?
|
| Accelerometry | 1 | 2016 | 73 | 0.040 |
Why?
|
| Clinical Coding | 1 | 2016 | 20 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 524 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2023 | 1254 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 58 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2017 | 541 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2017 | 264 | 0.040 |
Why?
|
| Focus Groups | 1 | 2017 | 338 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 39 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 151 | 0.030 |
Why?
|
| Fetus | 1 | 2019 | 575 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2015 | 24 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 363 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2017 | 205 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 29 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 533 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2019 | 397 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 57 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2015 | 42 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 727 | 0.030 |
Why?
|
| Linoleic Acid | 1 | 2015 | 34 | 0.030 |
Why?
|
| Fatty Acid Desaturases | 1 | 2015 | 20 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 26 | 0.030 |
Why?
|
| CD40 Antigens | 1 | 2015 | 53 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2352 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 196 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2014 | 26 | 0.030 |
Why?
|
| Adolescent Medicine | 1 | 2014 | 20 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2015 | 86 | 0.030 |
Why?
|
| Vitamin E | 1 | 2015 | 117 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2014 | 50 | 0.030 |
Why?
|
| Carbohydrates | 1 | 2014 | 50 | 0.030 |
Why?
|
| Amino Acids | 1 | 2017 | 389 | 0.030 |
Why?
|
| Estradiol | 1 | 2017 | 435 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 536 | 0.030 |
Why?
|
| Zinc Transporter 8 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Physical Endurance | 1 | 2015 | 254 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 95 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 717 | 0.030 |
Why?
|
| Forearm | 1 | 2014 | 113 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 502 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1009 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2013 | 42 | 0.030 |
Why?
|
| Population Groups | 1 | 2013 | 42 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 2149 | 0.030 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2013 | 29 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 25 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 759 | 0.030 |
Why?
|
| Population Growth | 1 | 2012 | 9 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2013 | 59 | 0.030 |
Why?
|
| Informed Consent | 1 | 2014 | 154 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 1126 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 945 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2014 | 384 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2015 | 264 | 0.030 |
Why?
|
| Static Electricity | 1 | 2012 | 87 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2013 | 323 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 407 | 0.030 |
Why?
|
| Athletes | 1 | 2015 | 318 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 342 | 0.030 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2012 | 61 | 0.030 |
Why?
|
| Placebos | 1 | 2012 | 193 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2014 | 300 | 0.030 |
Why?
|
| Milk | 1 | 2012 | 99 | 0.030 |
Why?
|
| Mammary Glands, Animal | 1 | 2012 | 119 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1353 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1916 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2017 | 1137 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 757 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2012 | 300 | 0.030 |
Why?
|
| Small-Area Analysis | 1 | 2010 | 9 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 893 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 553 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1141 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2012 | 198 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 765 | 0.020 |
Why?
|
| Fetal Weight | 1 | 2009 | 29 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 447 | 0.020 |
Why?
|
| Intestines | 1 | 2012 | 301 | 0.020 |
Why?
|
| Women's Health | 1 | 2011 | 247 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 2029 | 0.020 |
Why?
|
| Gravidity | 1 | 2008 | 4 | 0.020 |
Why?
|
| Coitus | 1 | 2008 | 23 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 294 | 0.020 |
Why?
|
| Psychology, Adolescent | 1 | 2008 | 58 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 264 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3507 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2008 | 72 | 0.020 |
Why?
|
| Contraceptive Agents, Female | 1 | 2008 | 31 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2011 | 318 | 0.020 |
Why?
|
| Contraception Behavior | 1 | 2008 | 68 | 0.020 |
Why?
|
| Fertility | 1 | 2008 | 108 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 333 | 0.020 |
Why?
|
| Counseling | 1 | 2010 | 343 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1536 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2012 | 969 | 0.020 |
Why?
|
| Bias | 1 | 2008 | 180 | 0.020 |
Why?
|
| Seasons | 1 | 2009 | 420 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 252 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2012 | 545 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 527 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2004 | 20 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2008 | 381 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2004 | 29 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1601 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 12178 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2014 | 1521 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 1503 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 1298 | 0.010 |
Why?
|